N
Noile-Immune Biotech
Innovative cancer immunotherapies utilizing the immune system to eradicate cancer cells
About Noile-Immune Biotech
Noile Immune Biotech is a clinical-stage biotechnology company dedicated to developing and commercializing novel cancer immunotherapy products. The company focuses on leveraging the immune system to target and eliminate cancer cells. Noile Immune Biotech collaborates with leading academic institutions, including the National Cancer Center (NCC) in Japan, to advance its research and development efforts. The company's primary market includes healthcare providers, research institutions, and pharmaceutical companies. Noile Immune Biotech generates revenue through partnerships, licensing agreements, and the commercialization of its proprietary immunotherapy products. The business model is centered around innovation in cancer treatment, aiming to provide effective and targeted therapies for patients.
Source: Dealroom company dataNews
Open roles
Noile-Immune Biotech in the Tokyo ecosystem
The Noile-Immune Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
BiGEN
Sosei CVC
Series B and later2 investors entered at this stage
- SKShibuya Kogyo
SBI Investment
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Noile-Immune Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Noile-Immune Biotech on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

